Valley Wealth Managers Inc. Invests $49,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Valley Wealth Managers Inc. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 47 shares of the biopharmaceutical company’s stock, valued at approximately $49,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Quent Capital LLC increased its stake in shares of Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 19 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its position in Regeneron Pharmaceuticals by 26.8% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 587 shares of the biopharmaceutical company’s stock valued at $565,000 after buying an additional 124 shares in the last quarter. Acadian Asset Management LLC raised its stake in Regeneron Pharmaceuticals by 37.2% during the first quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after buying an additional 16,856 shares during the last quarter. Cercano Management LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $36,953,000. Finally, Edgestream Partners L.P. purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $7,352,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on REGN shares. Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Barclays cut their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 3.3 %

NASDAQ:REGN opened at $756.81 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $753.69 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock’s fifty day moving average is $985.21 and its two-hundred day moving average is $1,032.97. The stock has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.